Enhanced sensitivity to IL-2 signaling regulates the clinical responsiveness of IL-12-primed CD8+ T cells in a melanoma model

Journal of Immunology

Volumn 186, Issue 9, 2011, Pages 5068-5077

  Lisiero, Dominique N ^a   Soto, Horacio ^a   Liau, Linda M ^a   Prins, Robert M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CONTROL; CANCER INHIBITION; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CROSS PRESENTATION; DRUG EFFICACY; DRUG POTENTIATION; DRUG SENSITIVITY; EFFECTOR CELL; IN VITRO STUDY; LYMPHOCYTE FUNCTION; LYMPHOCYTE SUBPOPULATION; MELANOMA; MEMORY CELL; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; UPREGULATION;

ANIMALS; BLOTTING, WESTERN; CD8-POSITIVE T-LYMPHOCYTES; CELL SEPARATION; DISEASE MODELS, ANIMAL; FLOW CYTOMETRY; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERLEUKIN-12; INTERLEUKIN-2; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; SIGNAL TRANSDUCTION;

EID: 79955532098     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1003317     Document Type: Article

References (63)

1. Rosenberg, S. A., N. P. Restifo, J. C. Yang, R. A. Morgan, and M. E. Dudley. 2008. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat. Rev. Cancer 8: 299-308.
2. Hinrichs, C. S., R. Spolski, C. M. Paulos, L. Gattinoni, K. W. Kerstann, D. C. Palmer, C. A. Klebanoff, S. A. Rosenberg, W. J. Leonard, and N. P. Restifo. 2008. IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy. Blood 111: 5326-5333.
3. Klebanoff, C. A., L. Gattinoni, P. Torabi-Parizi, K. Kerstann, A. R. Cardones, S. E. Finkelstein, D. C. Palmer, P. A. Antony, S. T. Hwang, S. A. Rosenberg, et al. 2005. Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. Proc. Natl. Acad. Sci. USA 102: 9571-9576.
4. Hinrichs, C. S., Z. A. Borman, L. Cassard, L. Gattinoni, R. Spolski, Z. Yu, L. Sanchez-Perez, P. Muranski, S. J. Kern, C. Logun, et al. 2009. Adoptively transferred effector cells derived from naive rather than central memory CD8+ T cells mediate superior antitumor immunity. Proc. Natl. Acad. Sci. USA 106: 17469-17474.
5. Macgregor, J. N., Q. Li, A. E. Chang, T. M. Braun, D. P. Hughes, and K. T. McDonagh. 2006. Ex vivo culture with interleukin (IL)-12 improves CD8 (+) T-cell adoptive immunotherapy for murine leukemia independent of IL-18 or IFN-gamma but requires perforin. Cancer Res. 66: 4913-4921.
6. Rosenberg, S. A., B. S. Packard, P. M. Aebersold, D. Solomon, S. L. Topalian, S. T. Toy, P. Simon, M. T. Lotze, J. C. Yang, C. A. Seipp, et al. 1988. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N. Engl. J. Med. 319: 1676-1680.
7. Gattinoni, L., C. A. Klebanoff, D. C. Palmer, C. Wrzesinski, K. Kerstann, Z. Yu, S. E. Finkelstein, M. R. Theoret, S. A. Rosenberg, and N. P. Restifo. 2005. Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. J. Clin. Invest. 115: 1616-1626.
8. Prins, R. M., N. Craft, K. W. Bruhn, H. Khan-Farooqi, R. C. Koya, R. Stripecke, J. F. Miller, and L. M. Liau. 2006. The TLR-7 agonist, imiquimod, enhances dendritic cell survival and promotes tumor antigen-specific T cell priming: relation to central nervous system antitumor immunity. J. Immunol. 176: 157-164.
9. Stanley, M. A. 2002. Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential. Clin. Exp. Dermatol. 27: 571-577.
10. Schön, M. P., and M. Schön. 2004. Immune modulation and apoptosis induction: two sides of the antitumoral activity of imiquimod. Apoptosis 9: 291-298. (Pubitemid 38986952)
11. Wagner, T. L., C. L. Ahonen, A. M. Couture, S. J. Gibson, R. L. Miller, R. M. Smith, M. J. Reiter, J. P. Vasilakos, and M. A. Tomai. 1999. Modulation of TH1 and TH2 cytokine production with the immune response modifiers, R-848 and imiquimod. Cell. Immunol. 191: 10-19. (Pubitemid 29054962)
12. Zhu, K. J., J. P. Cen, J. X. Lou, Q. Wang, X. Zhang, Y. Xu, X. Z. Chen, and H. Cheng. 2009. Imiquimod inhibits the differentiation but enhances the maturation of human monocyte-derived dendritic cells. Int. Immunopharmacol. 9: 412-417.
13. Hernández, J., S. Aung, K. Marquardt, and L. A. Sherman. 2002. Uncoupling of proliferative potential and gain of effector function by CD8(+) T cells responding to self-antigens. J. Exp. Med. 196: 323-333.
14. Schmidt, C. S., and M. F. Mescher. 1999. Adjuvant effect of IL-12: conversion of peptide antigen administration from tolerizing to immunizing for CD8+ T cells in vivo. J. Immunol. 163: 2561-2567.
15. Mescher, M. F., J. M. Curtsinger, P. Agarwal, K. A. Casey, M. Gerner, C. D. Hammerbeck, F. Popescu, and Z. Xiao. 2006. Signals required for programming effector and memory development by CD8+ T cells. Immunol. Rev. 211: 81-92.
16. Curtsinger, J. M., J. O. Valenzuela, P. Agarwal, D. Lins, and M. F. Mescher. 2005. Type I IFNs provide a third signal to CD8 T cells to stimulate clonal expansion and differentiation. J. Immunol. 174: 4465-4469.
17. Curtsinger, J. M., D. C. Lins, and M. F. Mescher. 2003. Signal 3 determines tolerance versus full activation of naive CD8 T cells: dissociating proliferation and development of effector function. J. Exp. Med. 197: 1141-1151.
18. Derynck, R., R. J. Akhurst, and A. Balmain. 2001. TGF-beta signaling in tumor suppression and cancer progression. Nat. Genet. 29: 117-129.
19. Abken, H., A. Hombach, C. Heuser, K. Kronfeld, and B. Seliger. 2002. Tuning tumor-specific T-cell activation: a matter of costimulation? Trends Immunol. 23: 240-245.
20. Curtsinger, J. M., M. Y. Gerner, D. C. Lins, and M. F. Mescher. 2007. Signal 3 availability limits the CD8 T cell response to a solid tumor. J. Immunol. 178: 6752-6760.
21. Seliger, B., M. J. Maeurer, and S. Ferrone. 2000. Antigen-processing machinery breakdown and tumor growth. Immunol. Today 21: 455-464.
22. Brunda, M. J., L. Luistro, R. R. Warrier, R. B. Wright, B. R. Hubbard, M. Murphy, S. F. Wolf, and M. K. Gately. 1993. Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J. Exp. Med. 178: 1223-1230.
23. Fallarino, F., C. Uyttenhove, T. Boon, and T. F. Gajewski. 1996. Endogenous IL-12 is necessary for rejection of P815 tumor variants in vivo. J. Immunol. 156: 1095-1100.
24. Coughlin, C. M., K. E. Salhany, M. S. Gee, D. C. LaTemple, S. Kotenko, X. Ma, G. Gri, M. Wysocka, J. E. Kim, L. Liu, et al. 1998. Tumor cell responses to IFNgamma affect tumorigenicity and response to IL-12 therapy and antiangiogenesis. Immunity 9: 25-34. (Pubitemid 28361292)
25. Atkins, M. B., M. J. Robertson, M. Gordon, M. T. Lotze, M. DeCoste, J. S. DuBois, J. Ritz, A. B. Sandler, H. D. Edington, P. D. Garzone, et al. 1997. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clin. Cancer Res. 3: 409-417.
26. Colombo, M. P., and G. Trinchieri. 2002. Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine Growth Factor Rev. 13: 155-168. (Pubitemid 34229390)
27. Prins, R. M., C. J. Shu, C. G. Radu, D. D. Vo, H. Khan-Farooqi, H. Soto, M. Y. Yang, M. S. Lin, S. Shelly, O. N. Witte, et al. 2008. Anti-tumor activity and trafficking of self, tumor-specific T cells against tumors located in the brain. Cancer Immunol. Immunother. 57: 1279-1289.
28. Vo, D. D., R. M. Prins, J. L. Begley, T. R. Donahue, L. F. Morris, K. W. Bruhn, P. de la Rocha, M. Y. Yang, S. Mok, H. J. Garban, et al. 2009. Enhanced antitumor activity induced by adoptive T-cell transfer and adjunctive use of the histone deacetylase inhibitor LAQ824. Cancer Res. 69: 8693-8699.
29. Overwijk, W. W., M. R. Theoret, S. E. Finkelstein, D. R. Surman, L. A. de Jong, F. A. Vyth-Dreese, T. A. Dellemijn, P. A. Antony, P. J. Spiess, D. C. Palmer, et al. 2003. Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J. Exp. Med. 198: 569-580.
30. Prins, R. M., S. K. Odesa, and L. M. Liau. 2003. Immunotherapeutic targeting of shared melanoma-associated antigens in a murine glioma model. Cancer Res. 63: 8487-8491.
31. Sampson, J. H., J. H. Carter, Jr., A. H. Friedman, and H. F. Seigler. 1998. Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma. J. Neurosurg. 88: 11-20.
32. Hong, J. J., S. A. Rosenberg, M. E. Dudley, J. C. Yang, D. E. White, J. A. Butman, and R. M. Sherry. 2010. Successful treatment of melanoma brain metastases with adoptive cell therapy. Clin. Cancer Res. 16: 4892-4898.
33. Prins, R. M., and L. M. Liau. 2003. Immunology and immunotherapy in neurosurgical disease. Neurosurgery 53: 144-152; discussion 152-143.
34. Prins, R. M., and L. M. Liau. 2004. Cellular immunity and immunotherapy of brain tumors. Front. Biosci. 9: 3124-3136.
35. Yang, M. Y., P. M. Zetler, R. M. Prins, H. Khan-Farooqi, and L. M. Liau. 2006. Immunotherapy for patients with malignant glioma: from theoretical principles to clinical applications. Expert Rev. Neurother. 6: 1481-1494.
36. Sampson, J. H., G. E. Archer, D. A. Mitchell, A. B. Heimberger, J. E. Herndon, II, D. Lally-Goss, S. McGehee-Norman, A. Paolino, D. A. Reardon, A. H. Friedman, et al. 2009. An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme. Mol. Cancer Ther. 8: 2773-2779.
37. Liau, L. M., K. L. Black, N. A. Martin, S. N. Sykes, J. M. Bronstein, L. Jouben-Steele, P. S. Mischel, A. Belldegrun, and T. F. Cloughesy. 2000. Treatment of a patient by vaccination with autologous dendritic cells pulsed with allogeneic major histocompatibility complex class I-matched tumor peptides. Case report. Neurosurg. Focus 9: e8.
38. Liau, L. M., R. M. Prins, S. M. Kiertscher, S. K. Odesa, T. J. Kremen, A. J. Giovannone, J. W. Lin, D. J. Chute, P. S. Mischel, T. F. Cloughesy, and M. D. Roth. 2005. Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin. Cancer Res. 11: 5515-5525.
39. Sampson, J. H., G. E. Archer, D. A. Mitchell, A. B. Heimberger, and D. D. Bigner. 2008. Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma. Semin. Immunol. 20: 267-275.
40. Sanges, R., F. Cordero, and R. A. Calogero. 2007. oneChannelGUI: a graphical interface to Bioconductor tools, designed for life scientists who are not familiar with R language. Bioinformatics 23: 3406-3408.
41. Rabinovich, B. A., Y. Ye, T. Etto, J. Q. Chen, H. I. Levitsky, W. W. Overwijk, L. J. Cooper, J. Gelovani, and P. Hwu. 2008. Visualizing fewer than 10 mouse T cells with an enhanced firefly luciferase in immunocompetent mouse models of cancer. Proc. Natl. Acad. Sci. USA 105: 14342-14346.
42. Shu, C. J., S. Guo, Y. J. Kim, S. M. Shelly, A. Nijagal, P. Ray, S. S. Gambhir, C. G. Radu, and O. N. Witte. 2005. Visualization of a primary anti-tumor immune response by positron emission tomography. Proc. Natl. Acad. Sci. USA 102: 17412-17417.
43. Johnson, L. A., R. A. Morgan, M. E. Dudley, L. Cassard, J. C. Yang, M. S. Hughes, U. S. Kammula, R. E. Royal, R. M. Sherry, J. R. Wunderlich, et al. 2009. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 114: 535-546.
44. Prins, R. M., D. D. Vo, H. Khan-Farooqi, M. Y. Yang, H. Soto, J. S. Economou, L. M. Liau, and A. Ribas. 2006. NK and CD4 cells collaborate to protect against melanoma tumor formation in the brain. J. Immunol. 177: 8448-8455. (Pubitemid 44893807)
45. Craft, N., K. W. Bruhn, B. D. Nguyen, R. Prins, L. M. Liau, E. A. Collisson, A. De, M. S. Kolodney, S. S. Gambhir, and J. F. Miller. 2005. Bioluminescent imaging of melanoma in live mice. J. Invest. Dermatol. 125: 159-165.
46. Kallies, A., A. Xin, G. T. Belz, and S. L. Nutt. 2009. Blimp-1 transcription factor is required for the differentiation of effector CD8(+) T cells and memory responses. Immunity 31: 283-295.
47. Willinger, T., T. Freeman, M. Herbert, H. Hasegawa, A. J. McMichael, and M. F. Callan. 2006. Human naive CD8 T cells down-regulate expression of the WNT pathway transcription factors lymphoid enhancer binding factor 1 and transcription factor 7 (T cell factor-1) following antigen encounter in vitro and in vivo. J. Immunol. 176: 1439-1446.
48. Yuan, J., S. Gnjatic, H. Li, S. Powel, H. F. Gallardo, E. Ritter, G. Y. Ku, A. A. Jungbluth, N. H. Segal, T. S. Rasalan, et al. 2008. CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit. Proc. Natl. Acad. Sci. USA 105: 20410-20415.
49. Duvall, M. G., M. L. Precopio, D. A. Ambrozak, A. Jaye, A. J. McMichael, H. C. Whittle, M. Roederer, S. L. Rowland-Jones, and R. A. Koup. 2008. Polyfunctional T cell responses are a hallmark of HIV-2 infection. Eur. J. Immunol. 38: 350-363.
50. Xiao, Z., K. A. Casey, S. C. Jameson, J. M. Curtsinger, and M. F. Mescher. 2009. Programming for CD8 T cell memory development requires IL-12 or type I IFN. J. Immunol. 182: 2786-2794.
51. Kieper, W. C., M. Prlic, C. S. Schmidt, M. F. Mescher, and S. C. Jameson. 2001. Il-12 enhances CD8 T cell homeostatic expansion. J. Immunol. 166: 5515-5521.
52. Shu, C. J., C. G. Radu, S. M. Shelly, D. D. Vo, R. Prins, A. Ribas, M. E. Phelps, and O. N. Witte. 2009. Quantitative PET reporter gene imaging of CD8+ T cells specific for a melanoma-expressed self-antigen. Int. Immunol. 21: 155-165.
53. Morgan, R. A., M. E. Dudley, J. R. Wunderlich, M. S. Hughes, J. C. Yang, R. M. Sherry, R. E. Royal, S. L. Topalian, U. S. Kammula, N. P. Restifo, et al. 2006. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314: 126-129. (Pubitemid 44547756)
54. Yang, S., C. J. Cohen, P. D. Peng, Y. Zhao, L. Cassard, Z. Yu, Z. Zheng, S. Jones, N. P. Restifo, S. A. Rosenberg, and R. A. Morgan. 2008. Development of optimal bicistronic lentiviral vectors facilitates high-level TCR gene expression and robust tumor cell recognition. Gene Ther. 15: 1411-1423.
55. Díaz-Montero, C. M., S. El Naggar, A. Al Khami, R. El Naggar, A. J. Montero, D. J. Cole, and M. L. Salem. 2008. Priming of naive CD8+ T cells in the presence of IL-12 selectively enhances the survival of CD8+CD62Lhi cells and results in superior anti-tumor activity in a tolerogenic murine model. Cancer Immunol. Immunother. 57: 563-572.
56. Klebanoff, C. A., S. E. Finkelstein, D. R. Surman, M. K. Lichtman, L. Gattinoni, M. R. Theoret, N. Grewal, P. J. Spiess, P. A. Antony, D. C. Palmer, et al. 2004. IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells. Proc. Natl. Acad. Sci. USA 101: 1969-1974.
57. Kaufmann, D. E., D. G. Kavanagh, F. Pereyra, J. J. Zaunders, E. W. Mackey, T. Miura, S. Palmer, M. Brockman, A. Rathod, A. Piechocka-Trocha, et al. 2007. Upregulation of CTLA-4 by HIV-specific CD4+ T cells correlates with disease progression and defines a reversible immune dysfunction. Nat. Immunol. 8: 1246-1254.
58. Precopio, M. L., M. R. Betts, J. Parrino, D. A. Price, E. Gostick, D. R. Ambrozak, T. E. Asher, D. C. Douek, A. Harari, G. Pantaleo, et al. 2007. Immunization with vaccinia virus induces polyfunctional and phenotypically distinctive CD8(+) T cell responses. J. Exp. Med. 204: 1405-1416.
59. June, C. H. 2007. Adoptive T cell therapy for cancer in the clinic. J. Clin. Invest. 117: 1466-1476.
60. Baluna, R., and E. S. Vitetta. 1997. Vascular leak syndrome: a side effect of immunotherapy. Immunopharmacology 37: 117-132.
61. Kerkar, S. P., P. Muranski, A. Kaiser, A. Boni, L. Sanchez-Perez, Z. Yu, D. C. Palmer, R. N. Reger, Z. A. Borman, L. Zhang, et al. 2010. Tumor-specific CD8+ T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts. Cancer Res. 70: 6725-6734.
62. Kalia, V., S. Sarkar, S. Subramaniam, W. N. Haining, K. A. Smith, and R. Ahmed. 2010. Prolonged interleukin-2Ralpha expression on virus-specific CD8+ T cells favors terminal-effector differentiation in vivo. Immunity 32: 91-103.
63. Pipkin, M. E., J. A. Sacks, F. Cruz-Guilloty, M. G. Lichtenheld, M. J. Bevan, and A. Rao. 2010. Interleukin-2 and inflammation induce distinct transcriptional programs that promote the differentiation of effector cytolytic T cells. Immunity 32: 79-90.